Montreal, QC, Canada (Oct. 31, 2022) – 35Pharma, a biopharmaceutical company that designs and develops innovative biologics for cardiopulmonary diseases, announced today that it will present new preclinical results from its HS135 program at the 2022 American Heart Association Scientific Sessions (“AHA 2022”) taking place in Chicago, IL, USA (Nov. 5-7, 2022).
Details of the presentation are as follows:
In vivo Efficacy of HS135, a Novel Activin and GDF Trap for the Treatment of Pulmonary Hypertension (PH) and Metabolic Syndrome (MetS)
Abstract#: 10487
Poster#: MO4171
Session: Paving the Way: New Pre-Clinical Studies and Animal Models of Pulmonary Hypertension
Date: Monday, Nov 7., 2022
Time: 11:00 AM – 12:00 PM CT
Location: Zone 4, Science and Technology Hall, Level 3
The abstract was posted to the AHA Journals website and may be accessed here.
About 35Pharma and HS135
35Pharma is a biopharmaceutical company that designs and develops best-in-class transforming growth factor-beta (TGF-beta) superfamily ligand traps for cardio-pulmonary and -metabolic diseases. HS135 is a multi-specific receptor ectodomain ligand trap designed to achieve maximum neutralization of Activins & GDFs, clinically validated drivers of cardio-pulmonary and -metabolic disease. HS135 is undergoing IND enabling development.
Contact
Julia Schoelermann, VP Business Development, 35Pharma
info@35pharma.com
For more information, please visit www.35pharma.com
